CD169+ macrophages orchestrate plasmacytoid dendritic cell arrest and retention for optimal priming in the bone marrow of malaria-infected mice
Abstract
Plasmacytoid dendritic cells (pDCs) are the most potent producer of type I interferon (IFN), but how pDC is primed in vivo is poorly defined. Using a mouse model of severe malaria, we have previously established that upon priming by CD169+ macrophages (MPs), pDC initiates type I IFN-I secretion in the bone marrow (BM) of infected mice via cell-intrinsic TLR7 sensing and cell-extrinsic STING sensing. Herein we show that CD169+ MP and TLR7 sensing are both required for pDC arrest during priming, suggesting CD169+ MP are the source of TLR7 ligands. We establish that TLR7 sensing in pDC and chemotaxis are both required for pDC arrest and functional communication with CD169+ MP in the BM. Lastly, we demonstrate that STING sensing in CD169+ MP control pDC initiation of type I IFN production while also regulating pDC clustering and retention/egress from the BM. Collectively, these results link pDC acquisition of type I IFN-secreting capacity with changes in their motility, homing and interactions with CD169+ MP during infection. Thus, targeting this cellular interaction may help modulate type I IFN to improve outcomes of microbial infections and autoimmune diseases.
Editor's evaluation
This study presents valuable mechanistic findings demonstrating the requirement of CD169+ macrophage intrinsic STING signaling in regulating plasmacytoid DC motility/arrest and their activation. The evidence supporting the claims of the authors is solid, and their data suggest that adequate type I IFN production by pDC may also require macrophage intrinsic STING signaling. The work will be of great interest to the immunology community.
https://doi.org/10.7554/eLife.78873.sa0Introduction
Plasmacytoid dendritic cells (pDCs) (Colonna et al., 2004; Liu, 2005; Reizis, 2019) are equipped with the unique ability to rapidly secrete up to 1000 times more type I interferon (IFN) – both IFNα and IFNβ – than any other cell (Cella et al., 1999; Siegal et al., 1999; Asselin-Paturel et al., 2001). This is accounted for by several pDC-intrinsic and -extrinsic mechanisms. pDC-intrinsic features include the constitutive expression of the endosomal Toll-like receptors (TLR-) 7 and 9, which, respectively, recognize single stranded RNA and unmethylated CpG motifs containing DNA, leading to type I IFN production via MyD88 signaling and IRF7-mediated transcription, the constitutively highly expressed master regulator of their type I IFN producing capacity (Honda et al., 2005b; Honda et al., 2005a). Several pDC-extrinsic mechanisms are also involved in pDC activation, during which pathogen-derived material is provided to pDC by other cells, allowing further checkpoints of pDC activation (Reizis, 2019). However, the precise cell–cell interactions and dynamic requirements are still not well understood.
Type I IFN is a potent immunoregulatory cytokine that modulates hundreds of genes (Stetson and Medzhitov, 2006; Ivashkiv and Donlin, 2014; Barrat et al., 2019). It promotes early innate immune responses by favoring cell-autonomous defense mechanisms that rapidly restrict viral escape and growth. Type I IFN signaling induces the production of proinflammatory cytokines that enable the mobilization of innate immune defenses and set the stage for adaptive immune responses by enhancing antigen processing, presenting, and costimulatory capacities of antigen presenting cells. It also directly signals to activated T and B cells, promoting expression of anti-apoptotic molecules and orchestrating their differentiation into robust effector cells. In contrast to these beneficial effects, excess or dysregulated type I IFN production that occurs in the context of auto-immune diseases, suggests that type I IFN can also promote pathology (Barrat and Su, 2019). While in viral infections, type I IFN generally appears as an absolute requirement for effective antiviral immune responses, in bacterial (Mycobacterium tuberculosis, Listeria monocytogenes) and parasitic (Plasmodium) infections, type I IFN can favor deleterious outcomes (Auerbuch et al., 2004; Spaulding et al., 2016; Sharma et al., 2011; Donovan et al., 2017; Mooney et al., 2017). This is often associated with the production of an inappropriate set of inflammatory mediators that hampers or skews the development of an effective host response and promotes damaging inflammation, as also exemplified during SARS-CoV-2 infection (Tay et al., 2020).
Consistent with the described roles of type I IFN, pDC-derived type I IFN has been reported to be essential for host resistance against a range of viral infections (Reizis, 2019; Barrat and Su, 2019). It augments antiviral defense through the rapid activation of innate immune effector responses such as that of NK cells, monocytes, and neutrophils (Cervantes-Barragan et al., 2012; Cervantes-Barragan et al., 2007; Swiecki et al., 2013; Webster et al., 2018; Davidson et al., 2011; Lynch et al., 2018). It also modulates long-term CD8+ and CD4+ T cell survival and differentiation (Swiecki et al., 2010). pDC-derived type I IFN also promotes autoimmunity in SLE and dermatitis, systemic sclerosis, and type I diabetes (Barrat and Su, 2019; Hansen et al., 2015; Ah Kioon et al., 2018; Guiducci et al., 2010). Similarly, in a mouse model of severe lethal malaria, pDC-derived type I IFN can drive innate immune cell activation and robust inflammatory responses (Spaulding et al., 2016).
Several mechanisms are implicated in pDC initiation of type I IFN production in vivo. These include TLR7/9 pDC-intrinsic sensing of viral nucleic acids occurring as a result of direct pDC infection by viruses (Lee et al., 2007; Décembre et al., 2014; Macal et al., 2012; Hornung et al., 2004). Indirect sensing of pathogen-derived materials from non-pDC-infected cells also occurs via exosomes, shedding of immature virus-containing particles or even internalization of immune complexes (Webster et al., 2016; Webster et al., 2018; Décembre et al., 2014; Dreux et al., 2012; Takahashi et al., 2010; Björck et al., 2008; Rönnblom and Alm, 2001). pDC may therefore interact with other cells or cell-derived materials, for effective pathogen sensing and subsequent initiation of type I IFN production. In line with this concept, several studies have reported that pDC forms rapid clusters upon TLR7/9-mediated activation (Asselin-Paturel et al., 2005; Mittelbrunn et al., 2009; Brewitz et al., 2017). Systemic injection of synthetic TLR7/9 ligands or murine CMV infection induces pDC to migrate via CXCR3 and CCR7 to the marginal zone of spleens where they achieve peak production of type I IFN (Asselin-Paturel et al., 2005). pDC can also form stable immunological synapses with CD4+ T cells in vitro and upon TLR9-induced activation in the marginal zone/red pulp area (Asselin-Paturel et al., 2005). More recently, lymph node (LN) pDC behavior monitored during viral infection showed that they were recruited via CXCR3 or CCR5, respectively, by infected subcapsular CD169+ MP or activated CD8+ T cells to the site of priming and interaction with XCR1+ DC (Brewitz et al., 2017). Here, type I IFN from pDC promoted (i) local macrophage (MP)-antiviral response preventing virus spreading and more efficient antigen cross-presentation by DC to CD8+ T cells. Consistent with these findings, the formation of a dynamic TLR7-dependent interferogenic synapse between pDC- and virus-infected cells was also described in vitro, in which viral RNA and type I IFN were exchanged as possible mechanisms potentiating pDC scanning of infected cells while providing local and targeted delivery of type I IFN (Assil et al., 2019). These results therefore suggested that tissue trafficking and localization of pDC in situ is essential for them to undergo activation and for their optimal function. However, the precise spatiotemporal dynamics of pDC behavior in vivo at steady state and during infection or inflammation, and which cells and molecular events may regulate these events still remain poorly understood. Whether pDC initiation of type I IFN production is linked to their motile behavior in vivo is also largely uncharacterized.
We have previously established that (1) CD169+ MP prime pDC to initiate rapid type I IFN production in the bone marrow (BM) of mice infected with lethal Plasmodium yoelii (Py) YM (Spaulding et al., 2016), (2) pDC priming involved pDC-intrinsic TLR7 and pDC-extrinsic STING sensing, and (3) pDC arrested in the BM of infected mice at the time of peak type I IFN production (~1.5 days) using intravital microscopy (IVM) while they were highly motile in the BM of naive mice. pDC arrested near or potentially in contact with CD169+ MP, however, these MPs were also densely distributed throughout the BM making it difficult to establish a functional interaction. CD169+ MP are tissue-resident MP, which localizes at entry ports of lymphatics in dLNs and in splenic marginal zones. They capture and sample antigens from dead cells, and act as entry points for viruses and bacteria, subsequently initiating immune defenses (Sung et al., 2012; Kastenmüller et al., 2012; Perez et al., 2017; Miyake et al., 2007). Building on our prior work, we directly tested the hypothesis that pDCs need to arrest and communicate with CD169+ MP in order to properly activate and initiate type I IFN production. We assess if CD169+ MP take up Py-infected red blood cells (iRBCs), acting as a primary source of parasite-derived materials and signals for pDCs. We also explore the molecular sensing mechanisms underlying the establishment of this functional interaction. Our results show that both CD169+ MP and TLR7 sensing in pDC control pDC arrest. We also establish that STING sensing in CD169+ MP is necessary to prime pDC production of systemic type I IFN, and to allow pDC egress from the BM.
Results
CD169+ MP take up P. yoelii-iRBC in the BM
Since CD169+ MP are required to activate pDC in the BM of blood stage malaria-infected mice (Spaulding et al., 2016), we hypothesized that CD169+ MP initiate pDC activation after taking up Py-iRBC. Flow cytometric analysis revealed the presence of two subpopulations of CD169+ MP in the BM, which we defined phenotypically as F4/80hi CD169int (F4/80hi MP subset) and F4/80int CD169hi (CD169hi MP subset) (Figure 1—figure supplement 1A). To explore uptake of Py-iRBC by BM MP, we isolated RBC either from naive (uninfected RBCs, uRBC) or Py-infected mice, and labeled them with the red fluorescent dye tetramethylrhodamine (TAMRA-Red+) before transfer to WT recipient mice for FACS(Fluorescence Activated Cell Sorting) and IVM analyses of the BM (Figure 1—figure supplement 1B). This strategy enabled quantification and visualization of the initial uptake phase of Py-iRBC versus uRBCs in the BM. For in vivo visualization of CD169+ MP by IVM, mice were injected i.v. with anti-CD169-FITC (or CD169-PE in other experiments) mAb 16 hr prior to IVM imaging (Spaulding et al., 2016). This allowed to identify CD169+ MP in the BM as FITChi or PEhi cells, and labeled the same cell subsets as when the Cre recombinase is expressed under the promoter of the gene encoding for CD169 (Siglec1Cre) crossed to conditional Rosa26-lox-STOP-lox (LSL)-tomato or -YFP mice (Figure 1—figure supplement 1C). As early as 6 hr post-transfer of TAMRA-Red+ RBC, both F4/80hi and CD169hi BM MP took up significantly increased proportions of Py-infected iRBCs compared to uRBCs, with a ~10-fold higher uptake of infected relative to uninfected RBC in both CD169+ MP subsets (Figure 1A). Of note, we did not detect direct uptake of Py-iRBCs by pDC (Figure 1—figure supplement 2A). Py-iRBC uptake was also comparable in mice injected with anti-CD169 mAb or control isotype Ab prior to the transfer of TAMRA-Red+ iRBC, ruling out that the in vivo labeling of CD169+ MP interfered with Py-iRBC uptake (Figure 1—figure supplement 2B). Time-lapse IVM imaging confirmed Py-iRBC attachment and accumulation on CD169+ MP in the BM, and possibly internalization (Figure 1B and Figure 1—video 1). Thus, taken together these data show that both populations of CD169+ MP take up Py-iRBC in the BM of infected mice in vivo, consistent with the hypothesis that MP can present parasite-derived materials and provide activating signals to pDC.
CD169+ MP undergo massive loss and activation in Py-infected BM
If uptake of Py-iRBCs is indeed important for initial sensing of parasite-derived molecular patterns by MPs, we hypothesized that their activation status should be significantly modulated. Thus, we monitored both F4/80hi and CD169hi MP numbers and activation using various cell-surface markers related to type I IFN signaling (Sca-1), antigen presentation (MHC-II, CD80, CD86), and adhesion/uptake (ICAM-1, CD11a) following Py infection (Figure 1C–F and Figure 1—figure supplement 2C). We found a significant loss (>50%) of both MP subsets in the BM of Py-infected mice, that occurred between 30 and 36 hr post-infection as quantified by FACS analysis (Figure 1C) and IVM imaging of the tibial BM where the decrease in the overall BM MP numbers was also visualized in situ (Figure 1D). In addition, Sca-1, CD80 costimulatory molecule, and ICAM-1 integrin ligand expression were increased while CD11a was diminished, consistent with robust activation of both subsets of MP in response to Py infection (Figure 1E, F and Figure 1—figure supplement 1D). In summary, CD169+ MP in the BM of Py-infected mice are rapidly lost as they undergo robust activation.
CD169+ MP are required for pDC arrest in Py-infected BM
To directly link CD169+ MP priming of pDC to pDC motile behaviors, we next assessed whether Py-activated after Py infection control pDC arrest using time-lapse IVM of the tibial marrow. As an initial step, we established baseline pDC motile behaviors using several readouts comparing uninfected versus Py-infected WT mice at the time pDC produce peak type I IFN (i.e., 36 hr). We took advantage of the PTCRA-EGFP reporter mice, that express the enhanced green fluorescent protein (EGFP) under the control of the human pre-T cell receptor α (PTCRA) promoter. This promoter is selectively expressed in BM pDC (>95% of GFP+ cells, Figure 2—figure supplement 1A, Shigematsu et al., 2004) enabling us to visualize pDCs in vivo. For CD169+ MP visualization, mice were injected intravenously with the anti-CD169-PE mAb prior to IVM imaging (Figure 1—figure supplement 1C). To quantify pDC dynamic behavior, we utilized several metrics, which include track velocity (TV) that measures cell path length over time, displacement rate (DR) that measures overall distance cells moved (irrespective of path) over time, and mean square displacement (MSD) that classifies cell movement as random, confined, or processive and inform on the cell behavior. In WT uninfected mice, pDC was motile, exhibiting long tracks and a TV of 7.14 μm/min (Figure 2A, B and Figure 2—video 1), faster than their reported speed of 5 μm/min in LNs (Mittelbrunn et al., 2009), but slower than naive T cells in the LN that travel at 10–15 μm/min (Shigematsu et al., 2004). Based on their DR (1.5 μm/min) and MSD, pDC migrated through and explored a large volume of parenchymal tissue (~1350 μm2/hr), similar to LN lymphocytes (Mittelbrunn et al., 2009) and consistent with a scanning role in the BM (Figure 2B–D). In contrast, CD169+ MP were sessile, whether in naive or infected mice (Figure 2—figure supplement 1B). After Py infection, pDC tracks, TV (5.13 μm/min), DR (0.93 μm/min), and MSD were all significantly reduced. These quantitative measures are also consistent with their arrest visualized by IVM. Average mean values of these distinct measurements from independent mice reflected these findings. We next tested whether CD169+ MP were involved in pDC arrest after Py infection. We used (1) PTCRA-EGFP reporter mice crossed to siglec1DTR/DTR mice and (2) sublethally irradiated siglec1DTR/WT or control WT recipient mice (500 rads) reconstituted with WT PTCRA-EGFP reporter BM cells. These chimeras allowed us to rule out any substantial impact of the DTR transgene in pDC since WT PTCRA-EGFP+ pDC did not express the transgene. In siglec1DTR mice, whether chimeric or not, diphtheria toxin (DT) injection induced the selective depletion of both subsets of CD169+ MP (Figure 2—figure supplement 1C). Interestingly, IVM imaging of Py-infected DT-treated mice revealed much longer pDC tracks compared to untreated control mice (Figure 2E). Moreover, pDC DR and MSD were significantly increased compared to untreated mice (by ~50%, Figure 2F, G and Figure 2—video 2). As expected, in Py-infected, DT-treated PTCRA-EGFP/WT control chimeras, pDC had significantly reduced motility compared to uninfected. Average mean values from independent mice were also consistent with these conclusions. Thus, these data collectively establish that CD169+ MP control pDC dynamics during Py infection and suggest that pDC arrest is linked to their ability to initiate type I IFN production.
pDC arrest in Py-infected BM depends on TLR7-intrinsic signaling
To achieve type I IFN production, pDC requires TLR7-intrinsic sensing (Spaulding et al., 2016). If pDC arrest is indeed linked to their robust activation, we predicted that TLR7 sensing in pDC would also be required for their arrest. We first generated Tlr7−/y and WT PTCRA-EGFP reporter mice and monitored pDC motility in the tibial BM of Py infected (36 hr post-infection), or control uninfected live mice using IVM imaging. In both Tlr7−/y and WT uninfected mice, pDC was highly motile with long tracks and a comparable TV (respectively, 6.52 and 7.16 μm/min, Figure 3A, B and Figure 3—video 1). Interestingly, pDC in Tlr7−/y uninfected mice exhibit greater motility, suggesting that tonic TLR7 signals regulate pDC motility under steady-state conditions (Figure 3D). Following Py infection in WT mice, pDC motility was reduced by 31%, in terms of TV (4.92 μm/min) and 45% based on DR (~0.87 μm/min), as well as for MSD and slope of MSD averages (Figure 3B, D and Figure 3—video 2). In contrast, pDC in Py-infected Tlr7−/y mice did not arrest and continued migrating with similar speeds in terms of TV (7.05 μm/min) and DR (1.55 μm/min, Figure 3B, C) despite detectable measurable MSD reductions (Figure 3D) reflecting a more restricted migration pattern, but not arrest. Average mean values from independent mice also largely confirmed these conclusions, overall suggesting that while other factors than TLR7 signals control pDC motility, these remain insufficient to completely arrest them. Representing the proportion of pDC moving or arrested based on WT pDC threshold values (both for TV and DR) further highlights a comparable proportion of pDC moving or arrested in Py-infected Tlr7−/y mice and naive WT or Tlr7−/y mice, in contrast to Py-infected WT counterpart (Figure 3—figure supplement 1A). To further assess if cell-intrinsic TLR7 sensing mediated pDC arrest, we generated partial mixed BM chimera mice as above, in which WT recipient mice (CD45.1+) were grafted with either Tlr7−/y- or WT-PTCRA-EGFP reporter BM after sublethal irradiation. In these mice, ~30% of hematopoietic-derived cells originated from the donor reporter BM, allowing for tracking of Tlr7−/y or control WT PTCRA-EGFP+ pDC in an environment where ~70% of HSC-derived cells and all radioresistant cells, were intact for TLR7 signaling (Figure 3—figure supplement 1B). Consistent with the prior result (Figure 3A–D), Tlr7−/y pDC in infected chimeras exhibited long tracks and did not arrest while WT pDC had much shorter tracks and arrested, establishing that TLR7 signaling intrinsic to pDC, is required for them to stop during infection (Figure 3E, F and Figure 3—video 3). We also quantified pDC/CD169+ MP contact durations using a Kiss and Run algorithm (Imaris) as a measure of their possible interactions in chimeric mice and found that WT pDC significantly increased their contact times with the MP during infection (from ~2 to 16 min) whereas Tlr7−/y pDC interacted with the MP for comparable amounts of time (~4–5 min) whether mice were infected or not (Figure 3G). Thus, taken together, these results show that TLR7 sensing in pDC is required for their arrest and potential interactions with CD169+ MP in the BM of malaria-infected mice at the time pDC produce peak type I IFN. Since CD169+ MP are required for pDC arrest, it further suggests that MP are providing TLR7 ligands to pDC.
Altered chemotactic receptor and adhesion molecule expression on pDCs from Py-infected Tlr7−/y compared to WT mice
Because TLR7 sensing alters pDC dynamic behavior in vivo, we next hypothesized that TLR7 signaling likely modulated both their migratory and adhesion characteristics. Several chemotactic receptors (CXCR3, CXCR4, CX3CR1, CCR2, CCR5, CCR9) and adhesion molecules (CD11a, ICAM-1, VCAM-1) were reported to be expressed on pDC in naive mice and to contribute to their trafficking and ability to cluster upon activation (Asselin-Paturel et al., 2005; Brewitz et al., 2017; Sawai et al., 2013). We monitored cell-surface expression of chemokine receptors (CXCR3, CCR9, CXCR4, CX3CR1) and integrin ligands (ICAM-1, VCAM-1) on pDC in uninfected compared to Py-infected WT and Tlr7−/y mice (Figure 3—figure supplement 1C). While basal expression of these receptors and integrins was comparable in all groups of uninfected mice, CCR9 and CX3CR1 were significantly upregulated on pDC after infection in WT but not in Tlr7−/y mice. Significant increases in CXCR4 expression were not reliably detectable. In contrast, CXCR3 expression was significantly downregulated on pDC in both WT and Tlr7−/y mice, but to different extents (90% and 50%, respectively). Expression of ICAM-1, a ligand for the integrin LFA-1, was significantly upregulated in both WT and Tlr7−/y after infection, but the magnitude of upregulation remained substantially greater in WT mice (factor of ~3). Expression of CD11a, the alpha chain of LFA-1, was slightly decreased in Py-infected WT mice whereas expression did not change in Tlr7−/y mice. Lastly, expression of VCAM-1, ligand for the integrin VLA-4, was significantly reduced in both WT and Tlr7−/y during the infection, but to a lesser extent in Tlr7−/y mice. Collectively, these data link TLR7-mediated sensing by pDCs to changes in cell-surface expression of several chemotactic receptors and adhesion molecules that may contribute to modifications in pDC motility, homing, and/or arrest that occur following Py infection.
GαI-protein signaling is required for inducing pDC production of type I IFN
Since we found important modulations in chemokine receptor expression driven by TLR7 signaling, we hypothesized that chemotaxis was involved in pDC motility and arrest. To test this possibility, we injected Py-infected mice with either PBS (control) or pertussis toxin (PT), which blocks GαI-protein-coupled receptor signal transduction and related chemotaxis, and subsequently analyzed pDC motility, morphology, and type I IFN production (Figure 4 and Figure 4—video 1). In Py-infected PTCRA-EGFP reporter mice, PT treatment led to stronger immobilization of pDC compared to control mice, with shorter tracks and significantly lower DR (Figure 4A, B). pDC arrest was also concomitant with distinct morphological changes (Figure 4C). Notably, pDCs in PT-treated mice exhibited a round shape contrasting with the elongated dendritic shape observed in PBS-treated counterparts. Quantitative analysis of individual pDC length, surface, and shape factor (a measure of cell sphericity) further revealed significant differences in PT- versus PBS-treated Py-infected mice (Figure 4D). While after PT-treatment pDCs were immobile and unable to migrate, they were still viable in the BM and could potentially sense freely diffusing parasite-derived ligands. To determine whether PT treatment impacted the ability of pDC to make type I IFN, we carried out the same experiment in IfnbYFP/YFP reporter mice (Scheu et al., 2008), which revealed an 80% reduction in type I IFN-expressing pDC (YFP+) compared to control infected group (0.44% vs. 2.1% YFP+ pDCs, Figure 4E). Taken together with the imaging findings, this indicated that GαI-protein-dependent transduction was required to achieve maximal type I IFN production. Despite their drastic immobilization and morphological changes, pDC in PT-treated infected mice still modulated cell-surface expression of costimulatory (CD86) and adhesion (CD62L, ICAM-1, VCAM-1) molecules, as well as chemotactic receptors (CXCR3), compared to PBS-treated infected and uninfected control mice (Figure 4E). Specifically, expression of CD62L, ICAM-1, VCAM-1, and CXCR3 but not CD86, were significantly altered in PT- compared to PBS-treated Py-infected mice. These results show that blocking GαI-protein-coupled receptor signal transduction including chemotaxis, alters expression of most but not all of these markers, and the acquisition of type I IFN-secreting capacity by the pDC.
The fact that PT treatment prevented pDC motility, and both CD169+ MP and TLR7 sensing were required for pDC arrest and type I IFN production, suggested that pDCs do not encounter freely circulating TLR7 ligands in the BM but rather that such ligands must be presented by Py-activated CD169+ MP through close and durable contacts with pDC. However, as PT treatment has pleiotropic activity and may induce indirect effects on other cells, we next attempted to determine more specifically which chemotactic and adhesion receptors mediated pDC homing and activation. CXCR3 is significantly downregulated after Py YM (Figure 3—figure supplement 1B) and has been shown to promote chemotaxis of pDC to sites of priming in the LN (Brewitz et al., 2017). CXCR3 has two ligands, CXCL10 and CXCL9, which are highly expressed by monocytes and MP during infections (Soudja et al., 2014; Kastenmüller et al., 2013). Thus, we tested if CXCR3 was functionally contributing to pDC activation in the BM. We injected IfnbYFP/YFP mice at the time of infection both with anti-CXCR3 (CXCR3-173 clone) and anti-CXCL9 2A6.9.9 mAb, which blocks the CXCL10-binding site and neutralizes soluble CXCL9, respectively (Figure 4F). pDC in these mice expressed YFP at similar levels relative to control-isotype Ab-treated or non-treated mice (1.5–2%). Furthermore, Ab blocking of LFA-1 and VLA-4 integrins, with or without anti-CXCR3 mAb, also failed to decrease expression of type I IFN by the pDC, suggesting that none of the tested reagents were sufficient to recapitulate the in vivo effects of PT treatment on pDC activation. Collectively, these results suggested that pDC motility requires GαI-dependent chemotaxis. This process controls pDC homing to where TLR7 ligands are, and direct or indirect functional interactions with CD169+ MP to initiate type I IFN production.
STING signaling is not required for pDC arrest during Py infection
Since (1) STING signaling extrinsic to pDC is required for pDC to secrete type I IFN during Py YM infection (Spaulding et al., 2016), and (2) pDC arrest and possible functional interaction with MP, is linked to their full activation, we hypothesized that STING sensing could also contribute to pDC homing, arrest and communication with MP to initiate type I IFN production. To investigate these possibilities, we analyzed pDC motility in Sting1Gt/Gt PTCRA-EGFP reporter mice by IVM. In uninfected Sting1Gt/Gt mice, most pDC exhibited high motility while they arrested in Py-infected counterparts (Figure 5A and Figure 5—video 1). The majority of pDC tracks were confined and with reduced displacement from origin following the infection. While pDC DR and MSD slopes were significantly diminished compared to naive mice, the average pDC TV remained elevated (6.52 μm/min), similar to that of uninfected mice (6.33 μm/min) (Figure 5B–D). Such discordance between TV and DR usually means that cells exhibit a more confined migration pattern. Consistent with this interpretation, the MSD of pDC was significantly higher in Sting1Gt/Gt compared to WT-infected mice (Figure 5D). We next infected partial BM chimeras in which sublethally irradiated Sting1Gt/Gt or control WT mice were reconstituted with WT PTCRA-EGFP donor BM, allowing to monitor WT pDC motility in a Sting1Gt/Gt host where the majority of HSC-derived cells (~70%) and all radioresistant cells are deficient for STING. In these mice where we visualized WT pDC in a Sting1Gt/Gt host, pDC arrested and had longer contact durations with MP compared to control WT chimera and non-chimera mice (Figure 5E, F and Figure 5—video 2). Most interestingly, we observed that in both non-chimera Py-infected Sting1Gt/Gt mice, pDC clusters were significantly larger in volume than in WT control mice, by threefold on average, and in some cases exceeding WT clusters by tenfold (Figure 5G, H and Figure 5—videos 2 and 3). We also enumerated by FACS analysis higher numbers of pDC in the BM of Sting1Gt/Gt compared to WT IfnbYFP/YFP reporter Py-infected mice (Figure 5I), correlating with the significantly larger clusters of pDC quantified in the BM of Sting1Gt/Gt mice. As expected, the number of Ifnb-expressing pDC (YFP+) was significantly reduced compared to WT counterparts, despite increased pDC numbers. In addition, while still significantly modulated, expression of several chemotactic receptors (CXCR3, CCR9, CXCR4, CX3CR1) and the integrin VCAM-1, failed to undergo as much cell-surface modulation as in WT mice (Figure 5—figure supplement 1). This suggested that pDC in Sting1Gt/Gt mice may not receive appropriate signals to enable them to resume motility, leave clusters and egress from the BM. Taken together, these data establish that pDC-extrinsic, STING-dependent signals do not control pDC homing and arrest in the BM during Py infection, but that they may control pDC functional interactions with CD169+ MP and egress from the BM, thereby limiting their accumulation and/or retention in the BM.
STING signaling in CD169+ MP controls pDC production of type I IFN and egress from the BM
Next, we assessed if STING signaling specifically in CD169+ MP during Py YM infection controlled (1) initiation of type I IFN production by pDC, and (2) pDC accumulation versus egress from the BM. We bred siglec1Cre/Cre knock-in mice to Sting1Gt/Gt or Sting1F/F mice (where exons 3–5 of Sting1 were flanked with two LoxP sites) to generate siglec1Cre/WTSting1Gt/F mice, in which CD169+ MP lacked expression of functional STING. All these mice were also homozygous for the IfnbYFP reporter transgene, allowing us to monitor type I IFN expression by FACS. This reporter faithfully tracks with the production of IFNα and IFNβ cytokines as we established before (Spaulding et al., 2016). Upon Py YM infection, while ~2.2% of pDC (~4200 pDC/leg) in WT and Sting11Gt/WT control mice expressed IFNβ (YFP+ ICAM-1hi), we quantified a ~60% reduction in YFP+ pDC when STING was lacking in CD169+ MPs (Figure 6A), demonstrating that STING signaling in CD169+ MP was required for pDC priming of type I IFN producing capacity. Other markers strongly modulated on pDC upon activation (ICAM-1, CXCR3, CD86) underwent similar changes as in WT mice, suggesting either multistep activation or independent processes (Figure 6—figure supplement 1A). Interestingly, in these mice where CD169+ MP lacked STING, the number of pDC in BM was ~1.5 times higher than in WT or Sting11Gt/WT control groups (p value = 0.1, Figure 6B). Similar increases in numbers of pDC were also enumerated in the BM of whole-body STING-deficient (Sting1Gt/Gt) or CD169+ MP-depleted (DT-treated siglec1DTR/WT) infected mice, consistent with retention of pDC in BM when CD169+ MP or STING-dependent signals were absent (Figure 5G–I and Figure 5—videos 2 and 3). Collectively, these results show that STING signaling in CD169+ MP during Py infection, provide pDC with key signal(s) to initiate type I IFN production and egress from the BM.
STING-mediated activation of pDC is independent of CD169+ MP loss
Upon Py infection, a majority of CD169+ MP are rapidly lost (Figure 1). We hypothesized that STING signaling may control their loss and thus contribute to providing activating ligands and signals to pDC. We therefore assessed whether STING contributed to MP loss during Py infection. In whole-body Sting1Gt/Gt mice, CD169hi but not F4/80hi MP, were partially protected from loss compared to WT control mice (by ~50%, Figure 6C), suggesting that this may prevent optimal pDC priming. However, in siglec1Cre/WTSting1Gt/F mice where STING is selectively lacking in CD169+ MP, both MP populations underwent similar loss as in WT mice, suggesting STING deficiency extrinsic to MP, protects CD169hi MP from loss. However, in siglec1Cre/WTSting1Gt/F mice, pDC failed to initiate type I IFN transcription and accumulated in the BM compared to control groups (Figures 5I and 6B), consistent with a model in which STING signaling in CD169+ MP provide activating signals to pDC that are unrelated to their loss. Of note, MP activation 36 hr post-infection, as measured by cell-surface modulation of MHC-II, CD80, ICAM-1, and Sca-1, was mostly comparable in all infected groups, likely ruling out a general activation defect of STING-deficient MP (Figure 6—figure supplement 1B). In summary, these data uncouple MP loss that occurs during Py infection from STING-mediated priming of pDC by CD169+ MP.
Discussion
Here, we reveal a complex multi-cell choreography that orchestrates pDC production of type I IFN during malaria infection. We establish the existence of a functional interaction (direct or indirect) between CD169+ MP and pDC in vivo that is needed to license pDC priming of type I IFN production in vivo during this infection. We link pDC arrest to their optimal priming. We show that CD169+ MP take up parasite-infected RBCs in the BM. We find that both CD169+ MP and pDC-intrinsic TLR7 sensing are required for pDC arrest, suggesting that MP is providing TLR7 ligands to pDC. We also show that MP-intrinsic STING sensing is required to activate pDC production of type I IFN, and enable their egress/release from the BM after priming (Figure 6D).
These findings are therefore consistent with a model in which CD169+ MP in the BM act as first-line responders to infection, akin to other CD169+ MP found in the LN and spleen (Grabowska et al., 2018). Depletion of these MP prior to infection prevents type I production by pDCs (Spaulding et al., 2016), indicating that these antigen presenting cells are non-redundant and uniquely capable of providing Py ligands and/or other innate signals to pDC in the BM. The fact that depletion of CD169+ MP and cell-intrinsic lack of TLR7 prevent pDC arrest establishes that pDC motility, homing and functional interactions with MP are prerequisites to achieve type I IFN production. These results suggest that TLR7 ligands, which trigger pDC arrest and type I production, are also not freely diffusing in the BM and/or that in vivo, pDC require nucleic acids to be properly presented or packaged to access TLR7-containing endosomes in pDC. In either case, we propose that direct or indirect interactions with CD169+ MPs are required to deliver Py-derived ligands to pDCs in the BM. This finding is consistent with prior studies showing pDC sensing of hepatitis C-infected hepatocytes via viral RNA-containing exosomes (Dreux et al., 2012; Takahashi et al., 2010) or cellular particles containing Dengue virus (Décembre et al., 2014). pDC was also reported to be directly infected by specific viruses such as herpes simplex virus and arenaviruses, and to utilize specialized intracellular processes like autophagy to sense viral nucleic acids and initiate type I IFN production (Lee et al., 2007; Macal et al., 2012; Assil et al., 2019). Given the very low frequency and numbers of pDC but their rapid response, it is likely that pDC are largely using such indirect but more effective modes of recognition. The formation of specialized cell–cell structures between pDC and infected cells or cells presenting pathogen-derived molecules, is indeed proposed to mediate both uptake and sensing of TLR ligands and the local delivery of type I IFN in interferogenic synapses (Assil et al., 2019).
Proper clustering and arrest of pDCs is a TLR7 guided process. TLR7 is required in pDC for their arrest, and type I production, as well as extensive remodeling of pDC expression of chemokine receptors and adhesion molecules, likely promoting stable contacts with activated, Py-loaded MPs. In vivo, pDC are recruited via CXCR3- and CCR5-dependent chemotaxis to virus-infected subcapsular draining LN MP or CD8+ T cells, respectively, for local delivery of type I IFN, rapidly restricting early virus spreading while promoting effective T cell priming (Brewitz et al., 2017). Given that pDC expresses multiple chemotactic receptors, and some are significantly up- or downregulated during Py infection (e.g., CCR9, CXCR3, CX3CR1), these processes are likely to be redundant. Consistent with this interpretation, blockade of CXCR3-mediated chemotaxis failed to recapitulate all GαI-mediated chemotaxis blockade. Even co-blockade of several adhesion molecules (LFA-1, VLA-4) involved in classical leukocyte adhesion and clustering, did not abrogate the production of type I IFN by pDC, suggesting that other chemotactic and adhesion mechanisms are involved and further investigations are needed.
Finally, we establish TLR7-dependent arrest and interaction of pDC with CD169+ MP. We also show that full activation of pDC requires STING signaling in CD169+ MP and that MP control pDC arrest. It was therefore unexpected that we did not find STING controls pDC arrest. However, we revealed that in STING-deficient mice, pDC formed significantly greater size clusters and accumulated in higher numbers in the BM compared to WT counterparts. This result was confirmed in mice lacking STING in the radioresistant compartment and only in CD169+ MP, consistent with a model where STING-dependent signals control pDC egress from the BM, and as a consequence, the organization of pDC clusters. In our previous work (Spaulding et al., 2016), we reported that pDC numbers in the BM of Py-infected mice decreased after peak type I IFN production while that of blood pDC increased. Larger clusters and increased numbers of pDC in STING-deficient mice, and in mice with STING-deficient CD169+ MP, may indicate that pDC are not fully activating and thus remain docked, awaiting for additional signals. These large clusters of pDC are further evidence that pDC priming is spatially segregated in the BM and that activation signals are not freely diffusing. These results connect the choreography of the cell–cell signal transmissions with pDC changes in arrest and migration for efficient regulation. Other signals that need to be elucidated are likely to regulate these cellular interactions in vivo.
In particular, which STING-dependent signal(s) are delivered from Py-activated CD169+ MP to pDC remains unknown. STING was originally identified as a cytosolic nucleic-acid sensor, which triggering leads to the induction of a robust type I IFN response via IRF3 and NFkB, and a rapid antiviral state that enables the control of viral infections (Zhong et al., 2008; Ishikawa and Barber, 2008). While pDC can secrete type I IFN independently of type I IFN signaling during VSV and MCMV infections (Tomasello et al., 2018; Barchet et al., 2002), pDC are also known to require type I IFN autocrine signaling when responding to TLR7/9 synthetic ligands in vivo (Asselin-Paturel et al., 2005). Thus, type I IFN may be the STING-dependent missing signal given by CD169+ MP during malaria infection. Several studies provide evidence that CD169+ subcapsular marginal zone and sinus MP in the spleen and LN, respectively, may produce type I IFN in response to viral infections (VSV, Vaccinia, MCMV) (Gui et al., 2019; Brault et al., 2018; Gaidt et al., 2017). However, since STING also triggers the proinflammatory transcriptional regulator NFkB, other cytokines could be the missing signal. STING signaling can also initiate distinct inflammatory cell deaths and autophagy as a defense mechanism. Among STING-mediated cell death, lysosomal cell death, pyroptosis, necroptosis, and NETosis were described to occur in myeloid cells in response to cGAS-STING sensing/signaling of viral DNA (Gui et al., 2019; Brault et al., 2018; Gaidt et al., 2017; Lood et al., 2016). While we observed a major loss of CD169+ MP in the BM (>60%) of Py-infected WT mice when type I IFN levels peak (30–36 hr), STING-deficient MP underwent similar loss, most likely excluding STING involvement in MP death. However, STING-driven autophagy could provide live CD169+ MP with Py-derived nucleic acids and other products for optimal presentation to pDC.
STING is generally shown to require cGAS for cytosolic double stranded DNA recognition (Sharma et al., 2011) and the production of STING-activating cyclic dinucleotides second messengers (Chen et al., 2016). Our results are discrepant with a prior study that also used lethal murine Py YM, and concluded that STING sensing of Py parasites in pDC prevented strong type I IFN responses by pDC through pDC-intrinsic SOCS1-mediated inhibition of TLR7/MyD88 signaling (Yu et al., 2016). In our previous work, as well as that of other groups (Spaulding et al., 2016; Sharma et al., 2011), blocking type I IFN production and signaling, increased mouse resistance to severe Py YM and P. berghei and non-lethal P. chabaudi and Py 17XNL murine malaria, respectively. We neither noted increased type I IFN levels in Sting1Gt/Gt mice, nor increased IFNβ production by STING-deficient pDC, and Sting1Gt/Gt mice did not exhibit greater resistance to Py YM either. Also, while the STING pathway may be active in pDCs, current experimental evidence is scarce (Reizis, 2019; Bruni et al., 2015), consistent with our finding that STING sensing occurs in the CD169+ MP, extrinsically to pDCs. We favor the interpretation that the Py YM strain used in this previous work, is likely to exhibit genetic differences with the repository Py YM strain MRA-755 we have used, which may account for the different outcomes. However, taken together, our results that type I IFN signaling negatively impact malarial infection outcomes, appear to be more consistent with the general consensus across several murine models of infection and laboratories.
In conclusion, our analysis of the dynamic behavior of pDC in vivo by IVM directly in the BM of mice undergoing severe murine malaria, reinforce a model in which pDC sensing of their ligands in vivo is a highly coordinated and orchestrated process. We establish that CD169+ MPs, a subset of tissue-resident MP that act as essential sentinels of the immune system constantly sampling the lymph and blood (Sung et al., 2012; Kastenmüller et al., 2012; Perez et al., 2017; Miyake et al., 2007), play a key role in regulating pDC activation in vivo. While we establish the existence of a functional interaction between these MP and the pDC in the BM of malaria-infected mice, further investigations will be needed to determine (1) the nature of the STING-dependent signals derived from CD169+ MP that allow pDC to achieve type I IFN-producing capacity and egress the BM to the blood and (2) whether this interaction is direct or not, and may also take place in other tissues and infections or autoimmune diseases.
Materials and methods
Mice
C57BL/6J wild-type (WT B6), Tlr7−/y (Lund et al., 2004) (strain 8380, Jackson Labs), Ifnbmob/mob/Ifnb-yfp+/+ (denoted IfnbYFP/YFP) (Gaya et al., 2015) (strain 10818, Jackson Labs), Sting1Gt/Gt (Sauer et al., 2011) (strain 17537, Jackson Labs), Sting1F/F (strain 031670, Jackson Labs), Rosa26LoxP-STOP-LoxP(LSL)-tTomato (strain 007914, Jackson Labs), and Rosa26LSL-YFP (strain 006148, Jackson Labs) mice have been described and were purchased from the Jackson laboratory. PTCRA-EGFP mice (129 background) (Shigematsu et al., 2004) and were obtained from Dr. Boris Reizis (NYU, New York, NY) and backcrossed to WT B6 mice for 10 generations. Tlr7−/y and Sting1Gt/Gt PTCRA-GFP as well as Tlr7−/y and Sting1Gt/Gt, IfnbYFP/YFP reporter mice were obtained by intercross, respectively, for use in IVM and FACS assays. siglec1DTR/DTR and siglec1Cre/Cre mice, a kind gift from Dr. Masato Tanaka (Riken, Japan) (Miyake et al., 2007) expressed the human diphtheria toxin receptor (DTR) or the Cre recombinase knocked-in to the exon 1 of the CD169-encoding gene the mice. Mice were used as heterozygous for experiments (siglec1DTR/WT, siglec1Cre/WTSting1Gt/FIfnbYFP/YFP, Sting1Gt/FIfnbYFP/YFP, siglec1Cre/WTRosa26LSL-tTomato/WT, siglec1Cre/WTRosa26LSL-YFP/WT), obtained by intercrossing of the relevant strains above. All mice were housed and bred in specific pathogen-free conditions at the Albert Einstein College of Medicine. Eight- to twelve-week-old and sex-matched males and female mice were used for all experiments.
Partial BM chimeras siglec1DTR/WT or WT B6 recipient mice were exposed to 5 Gy total body irradiation (500 rads) and reconstituted with 2 × 106 BM cells isolated from either Tlr7−/y or WT PTCRA-EGFP reporter mice. Chimerism of reconstituted mice was checked ~6 weeks later in the blood, before infections were conducted. Blood chimerism of donor-derived HSC was ~30%.
Plasmodium infections
Request a detailed protocolPlasmodium yoelii yoelii (17X), clone YM parasites (stock MRA-755) was obtained from BEI Resources. P. yoelii YM-infected red blood cells (iRBCs) from a frozen stock (stored in liquid nitrogen in Alsever’s solution and 10% glycerol) were injected intraperitoneally (i.p.) into a eight- to twelve-week-old WT B6 mouse, and grown for ~4 days. When parasitemia reached 2–10%, 5 × 105 . yoelii YM iRBCs were inoculated intravenously (i.v.) in a volume of 200 μl PBS into each experimental mouse.
Preparation of cell suspensions for flow cytometry (FACS) analysis
Request a detailed protocolBlood was collected in K2 EDTA(Ethylenediaminetetraacetic) tubes and red blood cells lysed with NH4Cl buffer (0.83%, vol/vol). BM was harvested from the femur and tibia by removing epiphyses to expose marrow cavity and placing into a 0.5-ml Eppendorf with a punched hole in the bottom made with an 18.5 G needle, nested into a 1.5-ml Eppendorf tube. Tubes were next centrifuged at 10,000 × g, 4°C, and cells resuspended in media for further used for further analyses (see below).
Cell staining for FACS analysis
Request a detailed protocolCell suspensions were stained with LIVE/DEAD Fixable Aqua (Thermo Fisher Scientific) or Ghost Dye Red 780 (Tonbo) in PBS for 30 min at 4°C, then incubated with Fc-block CD16/32 (clone 2.4G2) for 20 min at 4°C. Cell suspensions were next incubated in Ab mixes in FACS buffer (2 mM EDTA, 2% fetal bovine serum [FBS], 0.02% sodium azide in PBS) for 20 min at 4°C. For cell counts, we utilized 50,000 counting beads (SpheroTech) added to cells isolated from one leg or one spleen. Stained cells were collected either on a FACS BD LSR-II or Aria III. A list of all mAbs and sera used in the study with full information is provided in Supplementary file 1. Data were analyzed using FlowJo version 9.6.2 (TriStar).
RBC labeling
Request a detailed protocolRed blood cells were harvested from uninfected or Py YM-infected WT B6 mice with ~20% parasitemia by submandibular puncture into K2 EDTA tubes and washed twice with 10 ml 1× Mg2+Ca2+-free PBS. Peripheral blood was pelleted by centrifugation at 800 × g and 4°C for 5 min. RBCs were gently resuspended up to a volume of 5 ml in 1× Mg2+Ca2+-free PBS, and overlaid on top of 5 ml room temperature Ficoll-Plus in a 15 ml Falcon tube which was centrifuged at 1000 × g for 15 min at 20°C without breaks. RBC pellet was washed in 5 ml Mg2+Ca2+-free PBS, before staining with 5 μM 5-carboxytetramethylrhodamine (TAMRA-Red, ThermoFisher Scientific, Catalog#C6121) in PBS 2% FBS for 20 min at 37°C, 5% CO2 and in the dark. Labeled RBCs were then washed in 10 ml PBS, and 50 μl of packed RBCs recovered in 200 μl PBS were injected i.v. by retro-orbital route into recipient mice.
PT and in vivo mAb treatments
Request a detailed protocolPT (Sigma Millipore #516560) was reconstituted in 100 mM sodium phosphate, 500 mM sodium chloride, pH 7.0 and stored at −80°C. Mice were treated with 2.5 µg/µl PT in 100 µl of 1× PBS, i.v. at the time of infection. For mAb injections, mice received 250 μg of each mAb as specified in the figure panel, i.v. 30 min prior infection (Supplementary file 1).
Two-photon preparation, imaging, and analysis
Request a detailed protocolIn vivo imaging of BM was conducted as described previously (Pitt et al., 2015). PTCRA-EGFP reporter mice were anesthetized with isoflurane (2.5–3% for induction, 1–2% for surgery/imaging) admixed in 1:1 O2: air mixture at a flow rate of 1 l/min. Once induction was achieved, a gas mask was secured over the nose and stabilized using Velcro on a stage maintained at 37°C. The mouse anesthetic plane was ensured through the lack of response to toe and/or tail pinches. Level of isoflurane was adjusted accordantly to ensure the mouse maintained appropriate sedation with a stead, non-labored respiratory rate between 60 and 80 breath/min. Leg hair was then shaved using a surgical blade and a small amount of soap and water to facilitate hair removal. Loose hair and residual soap/water were removed with a kimwipe and the leg dried. Subsequently, the mouse torso was secured on the stage with Velcro under the diaphragm so as to not interfere with breathing, and the leg stabilized with a piece of scotch tape with the mouse is a supine position and the foot everted to reveal the medial surface of the leg. Then, the medial aspect of the tibia was surgically exposed by making a small incision at the level of the medial malleolus, avoiding the saphenous artery, to expose the tibial bone. A window was secured to the leg using vet bond, sliding a small tooth of the window under the tibial bone and then fixed to the stage using screws. Then, the exposed bone was shaved using a microdrill to a 100-μm thickness. Once optimal thinness was achieved, a ring of vacuum grease was drawn around the imaging area, then filled with a drop of 37°C lactated ringers (Thermo Scientific Cat#R08432), and the mouse transferred to the microscope chamber maintained at 37°C. Images were collected on an Olympus FV-1000MPE upright laser scanning microscope using a MaiTai DeepSee Laser (Spectraphysics) set to a wavelength of 910–920 nm. BM was visualized using a ×25 NA 1.05 objective and magnified 1.5–2×. Time lapse stacks with 5 μm slices spanning a total depth of 50 μm were captured at an acquisition of 4.0 μs/pixel using. To visualize CD169+ MP, mice were intravenously injected with 5 μg of anti-CD169 (SER4) antibody (BD Pharmingen) conjugated to PE (or FITC for Py-iRBC uptake experiments), 16 hr prior to imaging (Gaya et al., 2015).
Movie analysis: 4D image sets were analyzed on Volocity 6.3 (Improvision). Tracking was conducted using semi-automated scripts using spot function. For pDC identification, Channel 3 subtracted from Channel 2 using imaging processing -> channel arithmatics function. XY diameter set to 10 μm, threshold 7 for brightness, max distance 8 μm, max gap 0. Filtered to include only pDCs tracked >300 s. For cell-contact duration between pDC and CD169+ MP, analysis was conducted using Kiss and Run Analysis built-in plugin extension between pDC spots and MP surfaces (Imaris, Matthew Gastinger). Distance transformation function used with threshold set to 5 μm for distance. Data obtained from contact durations were tallied up for all pDC in the field in contact with CD169+ MP. Data were pooled from three or more mice from independent experiments. Supplementary movies were assembled using After Effects (Adobe). Contrast and saturation were enhanced to allow for greater ease of pDC visualization above MP for inclusion in publication (post-analysis).
Two-dimensional plots were created at a higher resolution to our specification using Matlab. Instructions and script hyperlinked: ./XYZ plots/Read Me.docx; ./XYZ plots/XY_Plots_ZB_10082019.m.
Statistics
All statistical tests were run with GraphPad Prism 8. Significance is depicted as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. All graphs show mean ± standard error of the mean. The unpaired t-test was used for comparing two groups related to FACS data. Welch’s t-test was used for comparing two groups related to IVM analyses. Multiple linear regression analyses were applied to test if the factor conditions (time and group) predicted displacement for statistical analysis of the MSD plots, assuming a gaussian distribution of residual and least squares.
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting file; Source Data files have been provided for all figures. There is no restriction of access.
References
-
Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8Science Translational Medicine 10:eaam8458.https://doi.org/10.1126/scitranslmed.aam8458
-
Mouse type I IFN-producing cells are immature APCS with plasmacytoid morphologyNature Immunology 2:1144–1150.https://doi.org/10.1038/ni736
-
Type I interferon dependence of plasmacytoid dendritic cell activation and migrationThe Journal of Experimental Medicine 201:1157–1167.https://doi.org/10.1084/jem.20041930
-
Mice lacking the type I interferon receptor are resistant to listeria monocytogenesThe Journal of Experimental Medicine 200:527–533.https://doi.org/10.1084/jem.20040976
-
Virus-Induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivoThe Journal of Experimental Medicine 195:507–516.https://doi.org/10.1084/jem.20011666
-
A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infectionThe Journal of Experimental Medicine 216:1974–1985.https://doi.org/10.1084/jem.20181359
-
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensingNature Immunology 17:1142–1149.https://doi.org/10.1038/ni.3558
-
Plasmacytoid dendritic cells in immunityNature Immunology 5:1219–1226.https://doi.org/10.1038/ni1141
-
Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9The Journal of Experimental Medicine 207:2931–2942.https://doi.org/10.1084/jem.20101048
-
Regulation of type I interferon responsesNature Reviews. Immunology 14:36–49.https://doi.org/10.1038/nri3581
-
IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursorsAnnual Review of Immunology 23:275–306.https://doi.org/10.1146/annurev.immunol.23.021704.115633
-
Plasmacytoid dendritic cells protect from viral bronchiolitis and asthma through semaphorin 4a-mediated T reg expansionThe Journal of Experimental Medicine 215:537–557.https://doi.org/10.1084/jem.20170298
-
Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigensThe Journal of Clinical Investigation 117:2268–2278.https://doi.org/10.1172/JCI31990
-
Type I interferon in malaria: a balancing actTrends in Parasitology 33:257–260.https://doi.org/10.1016/j.pt.2016.12.010
-
A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupusThe Journal of Experimental Medicine 194:F59–F63.https://doi.org/10.1084/jem.194.12.f59
-
Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cellsThe Journal of Experimental Medicine 210:2151–2159.https://doi.org/10.1084/jem.20130443
-
The trinity of COVID-19: immunity, inflammation and interventionNature Reviews. Immunology 20:363–374.https://doi.org/10.1038/s41577-020-0311-8
-
Cell-Cell sensing of viral infection by plasmacytoid dendritic cellsJournal of Virology 90:10050–10053.https://doi.org/10.1128/JVI.01692-16
Article and author information
Author details
Funding
NIAID (AI103666)
- David Fooksman
- Gregoire Lauvau
NIH (T32 GM7288)
- Jamie Moore-Fried
NIH (F31 HL147470)
- Jamie Moore-Fried
The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.
Acknowledgements
We thank the AECOM FACS core facilities. We thank Ilseyar Akhmetzyanova for helping with initial training on intravital microscopy and Zachary Benet for providing the MATLAB script to make the displacement charts featured in this manuscript.
This work was funded by the National Institutes of Health Grants (NIH/NIAID) AI103666 and Hirschl Caulier Award to GL and AI128735 to DF and GL. JM was supported by NIH MSTP training grant T32 GM7288-46 and F31 HL147470.
Ethics
This study was carried out in strict accordance with the recommendations by the animal use committee at the Albert Einstein College of Medicine under protocol number #20171113 and 00001375. The institution is accredited by the 'American Association for the Use of Laboratory Animals' (DHEW Publication No. (NIH) 78-23, Revised 1978), and accepts as mandatory the NIH 'Principles for the Use of Animals'. All efforts were made to minimize suffering and provide humane treatment to the animals included in the study.
Copyright
© 2022, Moore-Fried, Paul et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,059
- views
-
- 175
- downloads
-
- 3
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Immunology and Inflammation
Chronic antigenic stimulation can trigger the formation of interleukin 10 (IL-10)-producing T-regulatory type 1 (TR1) cells in vivo. We have recently shown that murine T-follicular helper (TFH) cells are precursors of TR1 cells and that the TFH-to-TR1 cell transdifferentiation process is characterized by the progressive loss and acquisition of opposing transcription factor gene expression programs that evolve through at least one transitional cell stage. Here, we use a broad range of bulk and single-cell transcriptional and epigenetic tools to investigate the epigenetic underpinnings of this process. At the single-cell level, the TFH-to-TR1 cell transition is accompanied by both, downregulation of TFH cell-specific gene expression due to loss of chromatin accessibility, and upregulation of TR1 cell-specific genes linked to chromatin regions that remain accessible throughout the transdifferentiation process, with minimal generation of new open chromatin regions. By interrogating the epigenetic status of accessible TR1 genes on purified TFH and conventional T-cells, we find that most of these genes, including Il10, are already poised for expression at the TFH cell stage. Whereas these genes are closed and hypermethylated in Tconv cells, they are accessible, hypomethylated, and enriched for H3K27ac-marked and hypomethylated active enhancers in TFH cells. These enhancers are enriched for binding sites for the TFH and TR1-associated transcription factors TOX-2, IRF4, and c-MAF. Together, these data suggest that the TR1 gene expression program is genetically imprinted at the TFH cell stage.
-
- Genetics and Genomics
- Immunology and Inflammation
Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in vivo in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, NRTKs regulate activation, migration, and proliferation of immune cells. We found that the patients’ ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced pluripotent stem cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.